Evidence map›Paper›PMID 30479615›Full record

ArticleJournal of contemporary brachytherapy2018

Acute and late toxicities in localized prostate cancer patients treated with low-dose

Yuki Mukai, Narihiko Hayashi, Izumi Koike, Hisashi Kaizu, Shoko Takano, Madoka Sugiura, Eiko Ito, Mizuki Sato, Hiroji Uemura, Masahiro Yao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of contemporary brachytherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in oncology · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yuki MukaiDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Narihiko HayashiDepartment of Urology, Yokohama City University Graduate School of Medicine.
Izumi KoikeDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Hisashi KaizuDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Shoko TakanoDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Madoka SugiuraDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Eiko ItoDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Mizuki SatoDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Hiroji UemuraDepartment of Urology, Yokohama City University Medical Center, Yokohama, Japan.
Masahiro YaoDepartment of Urology, Yokohama City University Graduate School of Medicine.
Masaharu HataDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Yokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this analysis was to compare acute and late toxicities between low-dose-rate brachytherapy (LDR-BT) (110 Gy) in combination with 45 Gy in 25 fractions external beam radiation therapy (EBRT) and LDR-BT (160 Gy) alone for localized prostate cancer. MATERIAL AND

methodsOne hundred five consecutive patients with localized prostate cancer treated from May 2014 to May 2017 were included in this retrospective analysis. Sixty patients received combination therapy and 45 patients received BT monotherapy. The LDR-BT procedure was performed using

resultsThe median follow-up time was 28 months in both groups. Three-year effect rates were overall survival: 100% in both groups. The biochemical failure rate was 2.3% in the combination group and 0% in the monotherapy group (

conclusionsTo our knowledge, this is the first report to compare the GU and gastrointestinal toxicities between the combination therapy and BT monotherapy (160 Gy) for localized prostate cancer. Unexpectedly, there were more late GU toxicities (except for hematuria) in the BT monotherapy group.

Indexed as

low-dose-rate brachytherapyprostate cancerradiation therapytoxicity

Identifiers

PMID30479615
PMCPMC6251450
OpenAlexW2901469072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.